fda crackdown on compounded semaglutide Intensifies GLP-1 Compounding States cracking down on compounding

Lilly is also studying Zepbound for treatment of MASH (metabolic associated steatohepatitis) and has met its goal in a Phase 2 study

The analysis found that treatment with GLP-1RAs led to significant weight loss and improved glycaemic control in adults with mental illness taking psychotropics

"Sustainable treatment will likely require combination approaches, longer-term strategies, and therapies that reshape how the brain interprets energy balance, not just how much people eat," he said.

At 1st Optimal, we see this all the time

Get over it and keep going

Setting Realistic Expectations Pharmaceutical weight loss follows predictable patterns that differ from crash dieting or extreme caloric restriction